2021Annual Report年報ANNUAL REPORT 2021 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon, the whole or any part of the contents of this report.This report, for which the directors (the “Directors”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.香港聯合交易所有限公司（「聯交所」）GEM的特色GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有較高投資風險。有意投資的人士應瞭解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣的證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。本報告乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司（「本公司」）的資料。本公司董事（「董事」）願就本報告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成份，且並無遺漏任何事項，足以令致本報告或其所載任何陳述產生誤導。 深圳市海王英特龍生物技術股份有限公司 2021年年報1Contents目錄 PageCorporate Information 2公司資料Chairman’s Statement 4主席報告Management Discussion and Analysis 6管理層討論及分析Directors, Supervisors and Senior Management Profile 16董事、監事及高級管理層履歷Report of the Directors 24董事會報告Corporate Governance Report 42企業管治報告Report of the Supervisory Committee 56監事會報告Independent Auditor’s Report 57獨立核數師報告Consolidated Statement of Profit or Loss and Other Comprehensive Income 65綜合損益及其他全面收益表Consolidated Statement of Financial Position 66綜合財務狀況表Consolidated Statement of Cash Flows 68綜合現金流量表Consolidated Statement of Changes in Equity 70綜合權益變動表Notes to the Consolidated Financial Statements 71綜合財務報表附註Five Year Financial Summary 175五年財務摘要Group Property 176集團物業 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED ANNUAL REPORT 20212Corporate Information公司資料DirectorsExecutive DirectorsMr. Zhang Feng (Chairman)Mr. Zhou Hang (resigned on 8 February 2021)Mr. Huang Jian BoNon-Executive DirectorsMr. Zhang Yi Fei (appointed on 1 March 2021)Ms. Yu LinMr. Shen Da KaiMr. Xu Yan He (passed away on 21 March 2022)Independent Non-Executive DirectorsMr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian ZhouSupervisorsMr. Xiong Chu XiongMr. Jin GeMs. Cao YangMembers of Remuneration CommitteeMr. Poon Ka Yeung (Chairman of the Remuneration Committee)Mr. Zhang FengMr. Yick Wing Fat, SimonMembers of Audit CommitteeMr. Yick Wing Fat, Simon (Chairman of the Audit Committee)Mr. Poon Ka YeungMs. Yu LinMembers of Nomination CommitteeMr. Zhang Feng (Chairman of the Nomination Committee)Mr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian ZhouCompany SecretariesMr. Huang Jian Bo Ms. Fung Wai Sum董事執行董事張鋒先生（主席）周航先生（於二零二一年二月八日辭任）黃劍波先生非執行董事張翼飛先生（於二零二一年三月一日獲委任）于琳女士沈大凱先生徐燕和先生（於二零二二年三月二十一日逝世）獨立非執行董事易永發先生潘嘉陽先生章劍舟先生監事熊楚熊先生金戈先生曹陽女士薪酬委員會委員潘嘉陽先生（薪酬委員會主席）張鋒先生易永發先生審核委員會委員易永發先生（審核委員會主席）潘嘉陽先生于琳女士提名委員會委員張鋒先生（提名委員會主席）易永發先生潘嘉陽先生章劍舟先生公司秘書黃劍波先生馮慧森女士 深圳市海王英特龍生物技術股份有限公司 2021年年報3Corporate Information公司資料Compliance OfficerMr. Zhang FengAuthorised RepresentativesMr. Zhang Feng (appointed on 8 February 2021)Mr. Zhou Hang (resigned on 8 February 2021)Mr. Huang Jian BoAuditorsGrant Thornton Hong Kong LimitedLegal AdviserStephenson Harwood18th Floor, United Centre, 95 Queensway, Admiralty, Hong KongPrincipal BankChina Constructi